0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Subscribe to the journal
From The JAMA Network
JAMA Internal Medicine
Invited Commentary  | 
Measuring the Effectiveness of Androgen-Deprivation Therapy for Prostate Cancer in the Medicare Population:  Adequate Data Are Neither the Same as Nor the Enemy of Perfect Data
Quoc-Dien Trinh, MD, FRCSC; Deborah Schrag, MD, MPH
JAMA Internal Medicine
Original Investigation  | 
Physician Variation in Management of Low-Risk Prostate Cancer:  A Population-Based Cohort Study
Karen E. Hoffman, MD, MHSc, MPH; Jiangong Niu, PhD; Yu Shen, PhD; et al.
JAMA Internal Medicine
Original Investigation  | 
Fifteen-Year Survival Outcomes Following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer
Grace L. Lu-Yao, MPH, PhD; Peter C. Albertsen, MD; Dirk F. Moore, PhD; et al.
JAMA Internal Medicine
Invited Commentary  | 
It Is Time to Stop Screening for Prostate Cancer
Vinay Prasad, MD